These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 12801971

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
    Vadan R, Gheorghe LS, Constantinescu A, Gheorghe C.
    Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
    [Abstract] [Full Text] [Related]

  • 23. The use of infliximab in South-east Asian children with severe Crohn's disease.
    Lee WS.
    Pediatr Int; 2004 Apr; 46(2):198-201. PubMed ID: 15056252
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Infliximab is the drug we have been waiting for in Crohn's disease.
    Rutgeerts P.
    Inflamm Bowel Dis; 2000 May; 6(2):132-6. PubMed ID: 10833073
    [No Abstract] [Full Text] [Related]

  • 26. Infliximab and Crohn's QOL.
    Wicks AC, Thomas C, Curran R, Mayberry JF.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1831-2. PubMed ID: 12269979
    [No Abstract] [Full Text] [Related]

  • 27. Does smoking decrease the response to infliximab in patients with Crohn's disease?
    Parsi MA.
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S18-9. PubMed ID: 18816687
    [No Abstract] [Full Text] [Related]

  • 28. Treatment of oesophageal Crohn's disease with infliximab.
    Theodoropoulou A, Koutroubakis IE, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2004 Apr; 16(4):431-2. PubMed ID: 15028980
    [No Abstract] [Full Text] [Related]

  • 29. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
    Papa A, Felice C, Marzo M, Guidi L.
    Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
    [No Abstract] [Full Text] [Related]

  • 30. [Long-term efficacy and predictors of response to infliximab in Korean patients with Crohn's disease].
    Lee KM.
    Korean J Gastroenterol; 2013 May; 61(5):241-5. PubMed ID: 23905245
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Infliximab for Crohn's disease: more questions than answers.
    Freeman HJ.
    Can J Gastroenterol; 2001 Jun; 15(6):360-2. PubMed ID: 11429663
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001].
    Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA, Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
    Gastroenterol Hepatol; 2002 Mar; 25(3):162-9. PubMed ID: 11864540
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Inflammatory diseases of the intestines].
    Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P.
    Rev Med Suisse; 2006 Jan 18; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.